Changzhou Qianhong Biopharma Co Ltd Cash Flow-to-Debt Ratio
Changzhou Qianhong Biopharma Co Ltd cash flow-to-debt ratio. Changzhou Qianhong Biopharma Co Ltd (002550) has a Cash Flow-to-Debt Ratio of 0.61x as of September 2025, meaning its operating cash flow of CN¥156.34 Million could theoretically repay 1% of its total liabilities (CN¥255.86 Million) in one year. Check Changzhou Qianhong Biopharma Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Changzhou Qianhong Biopharma Co Ltd (2007–2025)
Cash flow-to-debt ratio of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025. Historical debt coverage capacity for Changzhou Qianhong Biopharma Co Ltd across 19 annual periods. Check 002550 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Changzhou Qianhong Biopharma Co Ltd Cash Flow-to-Debt Ratio by Year (2007–2025)
Changzhou Qianhong Biopharma Co Ltd cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Changzhou Qianhong Biopharma Co Ltd. For the full cash flow conversion analysis, see Changzhou Qianhong Biopharma Co Ltd cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.13x | CN¥361.36 Million | CN¥320.64 Million | ▼ -31.3% |
| 2024 | 1.64x | CN¥514.71 Million | CN¥313.87 Million | ▼ -10.2% |
| 2023 | 1.83x | CN¥533.33 Million | CN¥292.17 Million | ▲ +1051.4% |
| 2022 | -0.19x | CN¥-71.47 Million | CN¥372.53 Million | ▼ -172.3% |
| 2021 | 0.27x | CN¥103.56 Million | CN¥390.24 Million | ▼ -67.7% |
| 2020 | 0.82x | CN¥317.28 Million | CN¥386.35 Million | ▲ +205.8% |
| 2019 | 0.27x | CN¥161.55 Million | CN¥601.65 Million | ▲ +575.5% |
| 2018 | 0.04x | CN¥25.45 Million | CN¥640.11 Million | ▼ -73.4% |
| 2017 | 0.15x | CN¥88.52 Million | CN¥591.41 Million | ▼ -58.7% |
| 2016 | 0.36x | CN¥221.01 Million | CN¥609.33 Million | ▼ -31.8% |
| 2015 | 0.53x | CN¥286.50 Million | CN¥538.67 Million | ▼ -62.4% |
| 2014 | 1.42x | CN¥252.01 Million | CN¥178.06 Million | ▼ -15.5% |
| 2013 | 1.68x | CN¥160.47 Million | CN¥95.77 Million | ▼ -50.9% |
| 2012 | 3.41x | CN¥199.82 Million | CN¥58.54 Million | ▲ +102.4% |
| 2011 | 1.69x | CN¥146.82 Million | CN¥87.07 Million | ▲ +32.5% |
| 2010 | 1.27x | CN¥171.51 Million | CN¥134.75 Million | ▲ +4323.2% |
| 2009 | 0.03x | CN¥8.35 Million | CN¥290.19 Million | ▼ -90.8% |
| 2008 | 0.31x | CN¥54.36 Million | CN¥173.75 Million | ▼ -33.1% |
| 2007 | 0.47x | CN¥35.99 Million | CN¥76.95 Million | — |